June 22, 2022

Zulresso (brexanolone) has obtained an expanded indication to treat postpartum depression (PPD) in patients who are at least 15 years old.

  • In 2019, the FDA approved Zulresso to treat PPD in adults. The drug is administered via intravenous infusion under the supervision of a qualified healthcare professional.
  • A full course of treatment requires 60 hours and follows a recommended dosing schedule of:
    • 0 to 4 hours: Initiate with a dosage of 30mcg/kg of the patient’s weight per hour.
    • 4 to 24 hours: Increase dosage to 60mcg/kg/hour.
    • 24 to 52 hours: Increase dosage to 90mcg/kg/hour (or consider a dosage of 60mcg/kg/hour for individuals unable to tolerate 90mcg/kg/hour).
    • 52 to 56 hours: Decrease dosage to 60mcg/kg/hour.
    • 56 to 60 hours: Decrease dosage to 30mcg/kg/hour.
July 31, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in August

Read More
July 19, 2022

FDA Approves First Therapy for Repigmentation in Vitiligo

Read More
July 15, 2022

Zonisade Approved to Treat Seizures

Read More
July 14, 2022

Xalkori Granted New Indication to Treat Non-Cancerous Tumors

Read More